Results 61 to 70 of about 1,912 (177)

Brinzolamide/brimonidine fixed combination for open-angle glaucoma and ocular hypertension treatment: hypotensive efficacy and tolerability

Российский офтальмологический журнал
The literature review analyzes the data of 12-year clinical use of a fixed combination of 1% brinzolamide and 0.2 % brimonidine (BBFC) in the treatment of glaucoma and ocular hypertension.
S. Yu. Petrov, A. N. Zhuravleva, O. M. Filippova, A. V. Starostina, O. I. Markelova   +4 more
doaj   +1 more source

Comparative characteristics of eye drops used for the treatment of glaucoma in an experimental model of dry eye

Российский офтальмологический журнал
Purpose of the work is a comparative study of the effect of different concentrations of the excipient carbomer on the local bioavailability and local irritant effect of brinzolamide and timolol in an experimental model of dry eye syndrome (DES). Material
E. V. Blinova, E. A. Litvin, D. S. Blinov, A. A. Galchin, M. V. Shikh, I. S. Struts, K. D. Blinov, S. D. Yudina, O. V. Sergeeva, S. E. Zotov, E. V. Shikh   +10 more
doaj   +1 more source

Experience in Application of the Combinations Dorzolamide / Timolol and Brinzolamide / Timolol for the Prevention of Intraocular Hypertension in Patients with Silicone Oil Tamponade of the Vitreal Cavity

Oftalʹmologiâ
Purpose: to conduct a comparative analysis of the clinical efficacy of a fixed combination of antihypertensive drugs: brinzolamide 1 % = timolol 0.5 % and dorzolamide 2 % = timolol 0.5 % for the prevention of intraocular hypertension in patients with ...
A. N. Kazennov, A. D. Chuprov, I. A. Kazennova, A. S. Firsov   +3 more
doaj   +1 more source

Brinzolamide encapsulated β-cyclodextrin-chondroitin sulfate nanocomplexes anchored chitosan/polycaprolactone nanofibers as an ocular insert for glaucoma treatment

Materials Today Bio
Glaucoma ranked second among the causes of blindness globally, necessitates the development of novel and effective therapeutic strategy. Anti-glaucoma eye drops as a topical dosage form are still considered as a method of choice for glaucoma treatment ...
Haroon Iqbal, Dengming Zhou, Anam Razzaq, Haiyang Zhang, Run Xiao, Fu Lin, Yuanbo Liang   +6 more
doaj   +1 more source

Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension

Clinical Ophthalmology, 2013
Jess T Whitson,1 Tony Realini,2 Quang H Nguyen,3 Matthew G McMenemy,4 Stephen M Goode5 1University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 2West Virginia University Eye Institute, Morgantown, WV, 3Scripps Clinic, La Jolla, CA, 4Lone ...
Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM   +4 more
doaj  

Brinzolamide-timolol suspension: acceptability and side effect profile

Clinical Ophthalmology, 2011
MD Doherty, SG Fraser, PS PhelanSunderland Eye Infirmary, Sunderland, Tyne and Wear, UKBackground: This study aimed to determine the frequency, nature, and impact of side effects associated with the use of brinzolamide-timolol suspension, a topical ...
Doherty MD, Fraser SG, Phelan PS
doaj  

Brinzolamide [PDF]

, 2020
openaire   +1 more source

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension

Clinical Ophthalmology, 2015
Sourabh Sharma,1 Sameer Trikha,1 Shamira A Perera,1 Tin Aung1,2 1Glaucoma Department, Singapore Eye Research Institute, Singapore National Eye Centre, 2Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore ...
Sharma S, Trikha S, Perera SA, Aung T
doaj  

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Patient Preference and Adherence, 2014
Quang H Nguyen Division of Ophthalmology, Scripps Clinic, La Jolla, CA, USA Abstract: Glaucoma is one of the leading causes of blindness and is characterized by optic nerve damage that results in visual field loss.
Nguyen QH
doaj  

Treatment Persistence with Combination Eye Drops for Glaucoma: A Longitudinal Analysis Using Japanese Medical Claims Data

Ophthalmology and Therapy
Introduction Glaucoma is a chronic progressive disease and the leading cause of blindness, particularly among older individuals. Treatment persistence with intraocular pressure (IOP)-lowering therapy is essential to avoid visual impairment, although data
Kenji Kashiwagi, Miyuki Matsukawa, Rikiya Toda, Kana Okamoto, Daisaku Michikami   +4 more
doaj   +1 more source